For the year ending 2025-12-31, BIAF made $6,161,959 in revenue. -$14,909,754 in net income. Net profit margin of -241.96%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net revenue | 6,161,959 | 9,362,022 | ||
| Direct costs and expenses | 4,226,799 | 5,983,475 | ||
| Research and development | 1,383,359 | 1,461,227 | ||
| Clinical development | 705,744 | 321,655 | ||
| Selling, general and administrative | 9,913,729 | 9,943,473 | ||
| Depreciation and amortization | 504,836 | 605,637 | ||
| Total operating expenses | 16,734,467 | 18,315,467 | ||
| Loss from operations | -10,572,508 | -8,953,445 | ||
| Interest income | 23,385 | 17,610 | ||
| Interest expense | 44,372 | 92,475 | ||
| Other income | 40,490 | 10,323 | ||
| Other expense | 502,429 | 10,194 | ||
| Change in fair value of warrants issued | 3,810,278 | - | ||
| Loss before income tax expense | -14,865,712 | -9,028,181 | ||
| Income tax expense | 44,042 | 11,650 | ||
| Net loss | -14,909,754 | -9,039,831 | ||
| Basic EPS | -8.66 | -0.75 | ||
| Diluted EPS | -8.66 | -0.75 | ||
| Basic Average Shares | 1,721,082 | 12,125,029 | ||
| Diluted Average Shares | 1,721,082 | 12,125,029 | ||
bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (BIAF)